Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Animal & Veterinary

FDA Issues Final Guidance on Terminology for Veterinary Medicinal Products Adverse Event Reporting

October 8, 2014

The U.S. Food and Drug Administration issued a final guidance document today to help drug manufacturers submit accurate and consistent adverse event reports related to animal medicinal products, also known as animal drugs. The final guidance, GFI 143: Pharmacovigilance of Veterinary Medicinal Products: Controlled List of Terms outlines the terms that should be used when submitting an adverse event report to FDA. This guidance complements GFI 188, “Data Elements for Submission of Veterinary Adverse Event Reports to the Center for Veterinary Medicine,” which provides instructions for veterinary drug adverse event reporting. GFI 143 also includes steps to keep the lists of terms up to date.

Controlled lists of terms are important for assessing the safety and efficacy of veterinary medicinal products because they help ensure consistency and allow easier comparison between veterinary medicinal products and across product classes.

Contact FDA

240-276-9115 FAX
Issued by: FDA, Center for Veterinary Medicine

7519 Standish Place, HFV-1

Rockville, MD 20855

Page Last Updated: 01/25/2017
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English